Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Dianthus Therapeutics Inc shares valued at $4,158,442 were sold by Randhawa Simrat on Nov 14 ’25. At $38.14 per share, Randhawa Simrat sold 109,031 shares. The insider’s holdings dropped to 4,000 shares worth approximately $0.16 million following the completion of this transaction.
Also, Randhawa Simrat sold 87,507 shares, netting a total of over 3,221,445 in proceeds. Following the sale of shares at $36.81 each, the insider now holds 4,000 shares.
Before that, SIMRAT RANDHAWA had added 196,538 shares to its account. In a trade valued at $7,609,951, the Officer bought Dianthus Therapeutics Inc shares for $38.72 each.
As published in their initiating research note from Truist on October 14, 2025, Dianthus Therapeutics Inc [DNTH] has been a Buy and the price target has been revised to $56. Analysts at William Blair started covering the stock with ‘”an Outperform”‘ outlook in a report released in early July. As of December 20, 2024, TD Cowen has initiated its “Buy” rating for DNTH. Earlier on October 03, 2024, Oppenheimer initiated its rating. Their recommendation was “an Outperform” for DNTH stock.
Analyzing DNTH Stock Performance
On last trading session, Dianthus Therapeutics Inc [NASDAQ: DNTH] plunged -0.07% to $40.79. The stock’s lowest price that day was $40.33, but it reached a high of $41.705 in the same session. During the last five days, there has been a surge of approximately 5.35%. Over the course of the year, Dianthus Therapeutics Inc shares have jumped approximately 74.61%. Shares of the company reached a 52-week high of $43.67 on 11/17/25 and a 52-week low of $13.36 on 04/09/25.
Support And Resistance Levels for Dianthus Therapeutics Inc (DNTH)
According to the 24-hour chart, there is a support level at 40.18, which, if violated, would cause prices to drop to 39.57. In the upper region, resistance lies at 41.55. The next price resistance is at 42.32. RSI (Relative Strength Index) is 64.34 on the 14-day chart, showing neutral technical sentiment.
Is Dianthus Therapeutics Inc subject to short interest?
Stocks of Dianthus Therapeutics Inc saw a sharp steep in short interest on 2025-10-31 dropping by -0.93 million shares to 4.03 million. Data from Yahoo Finance shows that the short interest on 2025-09-30 was 4.96 million shares. A decline of -23.12% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 7.12 of the overall float, the days-to-cover ratio (short ratio) decline to 7.12.
Which companies own the most shares of Dianthus Therapeutics Inc (DNTH)?
In terms of Dianthus Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 59 in the next 12 months, up nearly 44.54% from the previous closing price of $40.82. Analysts anticipate Dianthus Therapeutics Inc stock to reach 100 by 2025, with the lowest price target being 51. In spite of this, 6 analysts ranked Dianthus Therapeutics Inc stock as Buy at the end of 2025. On July 26, 2024, Robert W. Baird assigned a price target of “an Outperform” to the stock and initiated coverage with a $58.
